Lead plaintiffs’ attorneys in the transvaginal mesh litigation have fired back at four law firms objecting to their share of an estimated $550 million in fees, accusing them of making false attacks and submitting bills “riddled with excessive entries, duplicative billing” and other problems.

In a Monday filing, Henry Garrard III, chairman of the fee and cost committee, said all four firms failed to demonstrate how their work contributed to the “common benefit” of all lawyers in the litigation over transvaginal mesh device.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]